IDEXX Laboratories is poised for growth in the pet healthcare market. Check out why I see a 50% upside in IDXX stock by FY27.

Q4 2024 Earnings Call Transcript February 3, 2025 Operator: Good morning, and welcome to the IDEXX Laboratories’ Fourth ...

IDEXX Laboratories, Inc. (NASDAQ:IDXX), a leader in veterinary diagnostics and software, has been navigating a complex market landscape characterized by fluctuating veterinary visit trends and ...

IDEXX Laboratories Inc (NASDAQ:IDXX) reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year, beating the ...

IDEXX Laboratories, Inc. IDXX posted fourth ... The gross margin expanded 144 basis points (bps) to 59.8% despite a 2.2% rise in the cost of revenues. Sales and marketing expenses rose 5.7% ...

Net Margin: IDEXX Laboratories's net margin excels beyond industry benchmarks, reaching 23.87%. This signifies efficient cost management and strong financial health. Return on Equity (ROE): IDEXX ...

IDEXX Q4 adjusted EPS rose 10% YoY to $2.53 ... which offset inflationary cost impacts, favorable business mix benefits from strong consumable growth, and higher Water gross margins.

With sustained inflationary pressure, IDEXX may struggle to keep its cost of revenues and operating expenses in check. In the third quarter of 2024, general and administrative and sales and ...

Detailed price information for Lennox International (LII-N) from The Globe and Mail including charting and trades.